Repositioning Candidate Details

Candidate ID: R1165
Source ID: DB08835
Source Type: experimental
Compound Type: small molecule
Compound Name: Spaglumic acid
Synonyms: N-Acetyl-L-β-aspartyl-L-glutamic acid; Spaglumic acid
Molecular Formula: C11H16N2O8
SMILES: CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O
Structure:
DrugBank Description: Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate. Spaglumic acid is a mast cell stabilizer. Thus it is used in allergic conditions such as allergic conjunctivitis. Specifically spaglumic acid is approved in Portugal under the brand name Naabak and in Greece under the brand name Naaxia for use in patients with allergic conjunctivitis.
CAS Number: 4910-46-7
Molecular Weight: 304.255
DrugBank Indication: Used in patients with allergic conjunctivitis.
DrugBank Pharmacology: --
DrugBank MoA: Spaglumic acid is a mast cell stabilizer. Mast cells are involved in producing an allergic response by releasing inflammatory mediators such as histamine. Mast cell stablizers block the release of histamine and other mediators by inhibiting mast cell degranulation, which is the process of releasing these mediators. Inhibition occurs through inhibition of specific calcium channels to stabilize the mast cell and prevent degranulation.
Targets: Glutamate carboxypeptidase 2 ligand
Inclusion Criteria: Therapeutic strategy associated